Compare CRUS & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRUS | IMVT |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.3B |
| IPO Year | 1997 | 2019 |
| Metric | CRUS | IMVT |
|---|---|---|
| Price | $117.52 | $34.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 17 |
| Target Price | ★ $136.67 | $48.63 |
| AVG Volume (30 Days) | 701.2K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.83 | N/A |
| EPS | ★ 3.69 | N/A |
| Revenue | ★ $1,997,379,000.00 | N/A |
| Revenue This Year | $0.89 | N/A |
| Revenue Next Year | $4.08 | N/A |
| P/E Ratio | $31.44 | ★ N/A |
| Revenue Growth | ★ 5.34 | N/A |
| 52 Week Low | $105.10 | $21.86 |
| 52 Week High | $180.42 | $45.42 |
| Indicator | CRUS | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 55.13 |
| Support Level | $106.27 | $26.01 |
| Resistance Level | $123.88 | $35.44 |
| Average True Range (ATR) | 4.33 | 1.59 |
| MACD | 0.34 | 0.46 |
| Stochastic Oscillator | 52.36 | 56.39 |
Cirrus Logic Inc is a supplier of low-power, low-latency, high-precision audio components that are used in a variety of applications, including smartphones, PCs, tablets, AR/VR headsets, wearables, home theater systems, automotive entertainment systems, and professional audio systems. The firm's products are organized into two streams: audio products and HPMS Products. These products include amplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters, and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, India, South Korea, and countries across the world.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.